Clinical Trial Update: Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

View source ↗

Summary

This is a completed observational, non-interventional real-world data collection study of Depo-Eligard (leuprolide acetate) at 7.5 mg, 22.5 mg and 45 mg in male…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Depo-Eligard (leuprolide acetate (depot formulation))

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Prostate Cancer | Status: COMPLETED